Garg Vipul Kumar, Tickoo Vidya, Prasad Virender Pratibh, Maturu Venkata Nagarjuna
Pulmonary Medicine, Yashoda Hospitals, Hyderabad, Telangana, India.
Endocrinology, Yashoda Hospitals, Hyderabad, Telangana, India.
BMJ Case Rep. 2023 Oct 9;16(10):e256788. doi: 10.1136/bcr-2023-256788.
Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity reaction to that occurs in patients with asthma or cystic fibrosis. Here, we report a case of a young female with bronchial asthma who presented to our hospital with worsening breathlessness on exertion. She was diagnosed to have ABPA and was initiated on oral itraconazole while continuing inhaled long acting beta-2 adrenergic agonist and medium dose inhaled corticosteroid (ICS) for her asthma. Three months after initiation of therapy, the patient had significant improvement in breathlessness. However, she had weight gain, facial puffiness, increased facial hair and development of striae on her inner thighs, calf and lower abdomen. Her serum cortisol levels were found to be suppressed and hence a diagnosis of iatrogenic Cushing's syndrome was made. Our case describes the potentially serious interaction between ICS and oral itraconazole, a treatment very commonly prescribed in patients with ABPA.
变应性支气管肺曲霉病(ABPA)是发生于哮喘或囊性纤维化患者的一种对[此处原文缺失相关内容]的超敏反应。在此,我们报告一例年轻女性支气管哮喘患者,因活动时呼吸困难加重前来我院就诊。她被诊断为ABPA,并开始口服伊曲康唑,同时继续吸入长效β2肾上腺素能激动剂和中剂量吸入性糖皮质激素(ICS)治疗哮喘。治疗开始三个月后,患者呼吸困难有显著改善。然而,她出现了体重增加、面部浮肿、面部毛发增多以及大腿内侧、小腿和下腹部出现条纹。发现她的血清皮质醇水平受到抑制,因此诊断为医源性库欣综合征。我们的病例描述了ICS与口服伊曲康唑之间潜在的严重相互作用,伊曲康唑是ABPA患者常用的一种治疗药物。